38 results
8-K
EX-99.1
IVVD
Invivyd Inc
31 May 24
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
7:12am
variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2
8-K
EX-99.2
IVVD
Invivyd Inc
31 May 24
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
7:12am
, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor
8-K
EX-99.1
IVVD
Invivyd Inc
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells
8-K
EX-99.1
IVVD
Invivyd Inc
7 May 24
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19
7:38am
major SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus
8-K
EX-99.1
ejy9zdlw
12 Apr 24
Invivyd Announces CEO Transition
7:36am
8-K
EX-99.1
iosxgbcuod8
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
8-K
EX-99.1
2r1cisequifz6ek0
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
8-K
EX-99.1
y3w fg1e78zvh5d
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
EX-99.1
uost8oe
9 Feb 24
Index to Consolidated Financial Statements
4:01pm